UPDATE 1-CVS to pay $20 mln to settle SEC fraud charges

(Adds details of allegations, comments, case citation, byline)

April 8 (Reuters) - CVS Caremark Corp, which operates the second-largest U.S. drugstore chain, will pay $20 million to settle U.S. Securities and Exchange Commission charges that it defrauded investors in 2009 by concealing significant financial setbacks and accounting improperly for an acquisition.

The SEC, which announced the settlement on Tuesday, said CVS failed while marketing a $1.5 billion bond offering in September 2009 to disclose having recently lost significant Medicare and contract revenue streams in its pharmacy benefits manager (PBM) business, including from the former Caremark Rx Inc that it bought in March 2007.

After CVS disclosed the problems on Nov. 5, 2009, which resulted in a 20-percent plunge in its share price, the company further misled investors by manipulating its "retention rate," thereby inflating its ability to retain business, the SEC said.

CVS was also accused of having in November 2009 manipulated accounting for its October 2008 purchase of Longs Drug Stores Corp. The SEC said the changes improperly boosted profit by as much as 11.7 cents per share for the third quarter of 2009, enabling CVS to exceed rather than miss analyst forecasts.

"CVS broke faith with investors," Andrew Ceresney, director of the SEC enforcement division, said in a statement. "The intentional misconduct by CVS breached the core principle of fair and accurate reporting of financial performance."

The Woonsocket, Rhode Island-based company did not admit or deny wrongdoing in agreeing to settle, and on Tuesday said it is not restating any financial results.

Separately, the SEC said Laird Daniels, CVS' senior vice president for international operations and business development, agreed to pay $75,000 and accept a one-year accounting ban to settle related charges over the Longs accounting.

In court papers, the SEC said Daniels, who in 2009 was a CVS retail controller, characterized the accounting changes as turning the Longs purchase into a "good guy" rather than a "bad guy" for CVS, referring to its impact on profitability.

Daniels, 44, lives in North Attleboro, Massachusetts, the SEC said. He also did not admit or deny wrongdoing. His lawyer Robert Cleary, a partner at Proskauer Rose specializing in white collar defense, declined to comment.

A shareholder lawsuit against CVS over the PBM disclosures remains pending in a federal court in Providence, Rhode Island. Joseph Fonti, a partner at Labaton Sucharow representing the shareholders, was not immediately available for comment.

The cases are SEC v CVS Caremark Corp, U.S. District Court, District of Rhode Island, No. 14-00177; and In re: Daniels, SEC Administrative Proceeding No. 3-15825.

(Reporting by Jonathan Stempel in New York; Editing by Alden Bentley)